Journal of Renal Nutrition
Volume 19, Issue 4 , Pages 259-266 , July 2009

Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients

  • Rodney G. Bowden, PhD

      Affiliations

    • Health, Human Performance, and Recreation, School of Education, Baylor University, Waco, Texas
    • Corresponding Author InformationAddress reprint requests to Rodney G. Bowden, PhD, Health, Human Performance, and Recreation, School of Education, Baylor University, One Bear Place, #97304, Waco, TX 76798-7313.
    • ,
  • Jean Jitomir, MS, RD

      Affiliations

    • Health, Human Performance, and Recreation, Baylor University, Waco, Texas
    • ,
  • Ronald L. Wilson, MD

      Affiliations

    • Central Texas Nephrology Associates, Waco, Texas
    • ,
  • Mindy Gentile, MS, RD, LD

      Affiliations

    • Brazos Kidney Center, Waco, Texas

Received 14 April 2008

References 

  1. Svensson M, Christensen JH, Solling J, et al. The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am J Kidney Dis. 2004;44:77–83
  2. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403–414
  3. Banning M. The role of omega-3 fatty acids in the prevention of cardiac events. Br J Nutr. 2005;14:503–508
  4. Castro IA, Barrosa LP, Sinnecker P. Functional foods for coronary heart disease risk reduction: a meta-analysis using a multivariate approach. Am J Clin Nutr. 2005;82:32–40
  5. Wang C, Harris WS, Chung M, et al. N-3 fatty acids from fish or fish-oil supplements, but not α-linolenic acids, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84:5–17
  6. Hugh P, Barrett R, Watts G. Kinetic studies of lipoprotein in the metabolic syndrome including effects of nutrition interventions. Curr Opin Lipidol. 2003;14:61–68
  7. Foulon T, Richard MJ, Payen N, et al. Effects of fish oil fatty acids on plasma lipids and lipoproteins and oxidant ± antioxidant imbalance in healthy subjects. Scand J Clin Lab Invest. 1999;59:239–248
  8. Leigh-Firbank EC, Minihane AM, Leake DS. Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. Br J Nutr. 2002;87:435–445
  9. National Institutes of Health. Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: third report. Washington, DC: US Government Printing Office; 2002;
  10. Khajehdehi P. Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients. J Ren Nutr. 2000;10:191–195
  11. Dyerberg J, Eckesen DC, Anderson PW, et al. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk marker in healthy males. An 8 week dietary intervention study. Eur J Clin Nutr. 2004;58:1062–1070
  12. Hsu H, Lee Y, Chen M. Effect of n-3 fatty acids on the composition and binding properties of lipoproteins in hypertriglyceridemic patients. Am J Clin Nutr. 2000;71:28–35
  13. Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1:182–192
  14. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298–304
  15. Demonty I, Chan YM, Pelled D. Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols. Am J Clin Nutr. 2006;84:1534–1542
  16. Harrison RA, Sagara M, Rajpura A, et al. Can foods with added soya-protein or fish oil reduce risk factors for coronary artery disease? A factorial randomized controlled trial. Nutr Metab Cardiovasc Dis. 2004;14:44–350
  17. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007;27:715–728
  18. Saifullah A, Watkins BA, Saha C, et al. Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients—a pilot study. Nephrol Dial Transplant. 2007;22:3561–3567
  19. Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, Bentley ME. Pill count adherence to prenatal multivitamin/mineral supplement use among low-income women. J.Nutr. 2005;135:1093–1101
  20. Lee J, Kusek J, Greene P, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) pilot study. Am J Hypertens. 1996;9:719–725
  21. Grundt H, Nilsen WT, Hetland O, et al. Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following longterm treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr. 2004;23:491–500
  22. Wu WH, Lu SC, Wang TF, et al. Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women. Eur J Clin Nutr. 2006;60:386–392
  23. Helland IB, Saugstad OD, Saarem K, et al. Supplementation of n-3 fatty acids during pregnancy and lactation reduces maternal plasma lipid levels and provides DHA to the infants. J Maternal Fetal Neonatal Med. 2006;19:397–406
  24. Galen P, Debree A, Mennen L, et al. Background and rationale of the Su.Fol.Om3 Study: double-blind randomized placebo controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acid on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging. 2003;7:428–435
  25. Higgins S, Carroll YL, McCarthy SN, et al. Susceptibility of LDL to oxidative modification in healthy volunteers supplemented with low doses of n-3 unsaturated fatty acids. Br J Nutr. 2001;85:23–31
  26. Malinowski JM, Metka K. Elevation of low-density lipoprotein cholesterol concentration with over-the-counter fish oil supplementation. Ann Pharmacother. 2007;41:1296–1300
  27. Bowden RG, Hebert S, Wilson R, et al. Comparison of lipid measures and risk stratification among end-stage renal disease patients. J Nephrol. 2007;21:212–218
  28. Hamazaki K, Itomura M, Huan M, et al. N-3 long-chain FA decrease serum levels of TG and remnant-like particle-concentration in humans. Lipids. 2003;38:353–358
  29. Bowden RG, Hebert S, Wilson R, et al. A cholesterol primer for health professionals. Cal J Health Promo. 2003;4:12–21
  30. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids—a review. Nutr Metab Cardiovasc Dis. 2000;10:28–37
  31. Tulenko TN, Sumner AE. The physiology of lipoproteins. J Nucl Cardiol. 2002;9:638–649
  32. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943–949
  33. Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106:2137–2142
  34. Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med. 2001;47:111–136
  35. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461–467

PII: S1051-2276(09)00052-1

doi: 10.1053/j.jrn.2009.01.030

Journal of Renal Nutrition
Volume 19, Issue 4 , Pages 259-266 , July 2009

Article Tools

* Image Usage & Resolution